Changes in US Clinician Waivers to Prescribe Buprenorphine Management for Opioid Use Disorder During the COVID-19 Pandemic and After Relaxation of Training Requirements
Joanne Spetz, Laurie Hailer, Caryl Gay, Matthew Tierney, Laura A. Schmidt, Bethany J. Phoenix, Susan Chapman
Abstract
This case series examines numbers of US clinicians receiving waivers from the Drug Enforcement Administration allowing them to prescribe buprenorphine for opioid use disorder before and during the COVID-19 pandemic.
Topics & Concepts
BuprenorphineCoronavirus disease 2019 (COVID-19)Opioid use disorderPandemicMedicineOpioid2019-20 coronavirus outbreakDrugSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PsychiatryVirologyInternal medicineInfectious disease (medical specialty)OutbreakDiseaseReceptorOpioid Use Disorder TreatmentHealthcare professionals’ stress and burnoutMusculoskeletal pain and rehabilitation